Date: 2015-05-14
Type of information: Resignation
Compound:
Company: Aegerion Pharmaceuticals (USA - MA)
Therapeutic area: Rare diseases - Genetic diseases - Metabolic diseases
Type agreement: resignation
Action mechanism:
Disease:
Details: * On May 14, 2015, Aegerion Pharmaceuticals announced that Mark Fitzpatrick, Aegerion\'s chief financial officer (CFO), has resigned. David Aubuchon, Aegerion\'s chief accounting officer, will serve as acting CFO in the interim. The transition between Mr. Fitzpatrick and Mr. Aubuchon will occur within the next 30 days. David Aubuchon has served as chief accounting officer of Aegerion since March of 2015. Prior to joining the Company, Mr. Aubuchon was corporate controller at Ocata Therapeutics since October 2013 and was corporate controller at Inspiration Biopharmaceuticals from July 2012 until December 2012. From 1998 through 2010, Mr. Aubuchon held a series of positions with increasing responsibility at Sepracor (now known as Sunovion Pharmaceuticals), most recently as vice president, corporate controller and chief accounting officer. Additionally, Mr. Aubuchon was previously an auditor at PricewaterhouseCoopers LLP. Mr. Aubuchon holds a B.S. degree from the University of Massachusetts, Amherst and an M.B.A. degree from Babson College. Mr. Aubuchon holds a CPA certificate from the Commonwealth of Massachusetts.
Financial terms:
Latest news:
